{"filings":[{"id":91688,"accession_number":"0001175680-26-000002","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoDyn holds investor call for corporate and clinical update; no material results disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held investor call on April 30, 2026 at 1:00 p.m. PT to provide corporate and clinical update.","Presentation materials furnished as Exhibit 99.1 titled 'Leronlimab – A Novel Therapeutic in CCR5+ Immuno-Oncology'.","No specific financial or trial data included in the 8-K or exhibit; update is forward-looking without new quantitative details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101925,"accession_number":"0001104659-26-033943","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.","Monthly payment of $1M in common stock to noteholders priced at lower of prior close or 5-day average.","Annual interest rate on both notes reduced to 5% from prior rate as part of extension.","Total principal unchanged at $57M; company avoids immediate cash repayment through equity issuance.","Extension provides near-term liquidity relief but adds ongoing dilution for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101924,"accession_number":"0001104659-26-023856","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises $17.5M via private placement of 81.4M units at $0.2153 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of ~81.4M units (share + warrant) to accredited investors for ~$17.5M in cash.","Warrants have a 5-year term, exercise price $0.26 per share, fully exercisable at issuance.","Direct sale of 3,944,773 shares for ~$1.0M on Jan 23, 2026 (no warrants).","SEPA with Yorkville: ~0.8M shares issued for ~$0.2M in Jan 2026.","Convertible note exchanges: $1.5M principal exchanged for ~5.9M common shares in Jan/Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118261,"accession_number":"0001104659-25-117154","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytoDyn agrees to settle securities class action for $500K cash and 49M shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement in principle: $500,000 cash plus 49 million shares for dismissal of all claims.","Agreement subject to final documentation, court approval, and other conditions.","No admission of fault or liability by CytoDyn; company will defend vigorously if settlement fails.","If unsettled, the securities class action could materially affect financial condition and results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118260,"accession_number":"0001104659-25-115056","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CytoDyn shareholders approve increase in authorized shares to 2.25B; all directors reelected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 1.75B to 2.25B shares; approved 671,591,768 For vs 69,716,006 Against.","All five director nominees elected: Tanya Urbach, Stephen Simes, Ryan Dunlap, Lishomwa Ndhlovu, Karen Brunke.","Advisory vote on executive compensation passed with 389,864,422 For, 108,351,482 Against.","Shareholders ratified CBIZ CPAs as auditor for FY ending May 31, 2026; vote 721,348,317 For.","Advisory vote on frequency of say-on-pay set at one year; 451,446,382 votes for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118259,"accession_number":"0001104659-25-105306","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.","Shares priced at 98% of lowest 3-day VWAP; Yorkville capped at 4.99% beneficial ownership.","Commitment fee of 1% paid in shares (half immediately, half at 6 months); structuring fee $25k.","Proceeds for working capital, debt repayment, and leronlimab PD-L1 program development.","No warrants or derivatives; registration statement to be filed for resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151617,"accession_number":"0001558370-25-007954","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CytoDyn swaps auditor from Marcum to CBIZ after Marcum resignation; no accounting disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor effective May 14, 2025; CBIZ CPAs P.C. engaged same day for FY ending May 31, 2025.","Marcum's attest business was acquired by CBIZ on Nov 1, 2024; substantially all attest staff joined CBIZ.","Marcum's FY 2024 audit report had no adverse opinion but noted substantial doubt about going concern.","No disagreements or reportable events between CytoDyn and Marcum during FY 2024 and interim through resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151616,"accession_number":"0001558370-25-006531","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CytoDyn appoints Robert E. Hoffman as CFO effective May 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hoffman replaces interim CFO Mitch Cohen; Cohen resigns effective May 12 with last day May 30.","Compensation includes $450,000 base salary, 40% target bonus, option for 1M shares, PSUs for 3.5M shares.","Hoffman has 30+ years biotech experience; previously CFO at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals.","Hoffman currently serves on boards of Esperion Therapeutics, TuHURA Biosciences, and Fibrobiologics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187449,"accession_number":"0001558370-24-015918","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytoDyn shareholders elect all director nominees at 2024 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Tanya Durkee Urbach, Stephen M. Simes, Ryan M. Dunlap, Lishomwa C. Ndhlovu, and Karen J. Brunke elected as directors for one-year terms.","Ratification of Marcum LLP as independent auditor for fiscal year ending May 31, 2025 approved with 619.8M votes for vs 9.1M against.","Advisory vote on named executive officer compensation approved with 316.0M for, 63.2M against.","Broker non-votes of 247.7M shares for director elections and say-on-pay due to broker discretionary voting rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203964,"accession_number":"0001558370-24-009701","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CytoDyn settles Amarex lawsuit for $12M cash payment and $14M liability elimination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amarex to pay CytoDyn $12 million total, with $10 million received upon execution.","Surety bond of $6.5 million released and cash collateral returned to CytoDyn.","CytoDyn's $14 million accounts payable to Amarex eliminated at no cost.","Mutual release of all claims ends litigation filed in October 2021.","CEO cites improved balance sheet and ability to advance leronlimab trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220618,"accession_number":"0001558370-24-009629","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"CytoDyn appoints Marcum LLP as new independent auditor effective June 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP engaged as independent registered public accounting firm effective June 28, 2024.","Marcum will audit CytoDyn's fiscal year ending May 31, 2024 and review Q1-Q3 2025.","Appointment approved by Audit Committee; no prior auditor disagreements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220617,"accession_number":"0001558370-24-008869","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.","Each unit: one common share and one warrant (exercise $0.21, 5-year term).","Placement agent received 13% cash fee and warrants to purchase ~7.9M shares (10-year term).","Follow-on offering netted ~$0.2M in proceeds.","Aggregate unregistered sales exceeded 5% of shares outstanding as of March 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220616,"accession_number":"0001558370-24-006814","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"CytoDyn dismisses BF Borgers as auditor after SEC permanent bar; replacement search underway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed BF Borgers on May 6, 2024, following SEC order on May 3 permanently barring the firm.","BF Borgers was engaged Oct 5, 2023 through May 3, 2024, but did not perform any audit of CytoDyn's financials.","No disagreements or reportable events existed between CytoDyn and BF Borgers during the engagement.","Audit Committee has begun search for new independent auditor for FY ending May 31, 2024; selection pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}